NCT06418061

Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

A Multicenter, Open-label, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI3005 in Subjects With Advanced Malignant Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 198 (estimated)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of IBI3005 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3005.

Conditions

• Unresectable
• Locally Advanced or Metastatic Solid Tumors

Interventions

Type	Name	Description
DRUG	IBI3005	Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)

Timeline

• Start date: 2025-01-08
• Primary completion: 2027-06-30
• Completion: 2027-12-31
• First posted: 2024-05-16
• Last updated: 2025-01-22

Locations

1 site across 1 country: China